Sort   by:  
 Page size 
ProteomicsPCMT1 generates the C-terminal cyclic imide degron on CRBN substrates
The E3 ligase substrate adapter cereblon (CRBN), the primary target of clinical agents thalidomide and lenalidomide, recognizes endogenous substrates bearing the C-terminal cyclic imide modification. Although C-terminal cyclic imides can form spontaneously, an enzyme that regulates the formation of ...
ORGANISM(S): Mus musculus (Mouse) Homo sapiens (Human) 
2025-12-05 | PXD061730 | Pride
Crbn Pcmt1 C-terminal cyclic imide Glul Ppa1 
ProteomicsEZH2 inhibition overcomes immunomodulatory drug (IMiD) resistance in multiple myeloma cell lines in a CRBN pathway dependent manner
Immunomodulatory agents (IMiDs) and the next-generation Cereblon (CRBN) E3 ligase modulators (CeLMoDs), targeting the Ikaros/Aiolos-IRF4-MYC axis, are effective therapies for multiple myeloma (MM) across all stages of disease. Resistance to treatment can be acquired following exposure, but a subset ...
ORGANISM(S): Homo sapiens (Human) 
2026-03-19 | PXD057933 | Pride
Ezh2 inhibition Myeloma Imid Crbn pathway 
UnknownEnhancement of the SESN2-SHP cascade by melatonin ameliorates hepatic gluconeogenesis by inhibiting the CRBN-BTG2-CREBH signaling pathway.
Not available
S-EPMC10393991 | biostudies-literature
UnknownTargeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.
Not available
S-EPMC5524534 | biostudies-literature
UnknownAZD7762 induces CRBN dependent BAG3 degradation through ubiquitin-proteasome pathway.
Not available
S-EPMC10720835 | biostudies-literature
UnknownRegulation of AMPK Activity by CRBN Is Independent of the Thalidomide-CRL4CRBN Protein Degradation Axis.
Not available
S-EPMC8228114 | biostudies-literature
UnknownLung-specific CRBN knockout attenuates influenza a virus-induced acute lung injury in mice: a potential therapeutic approach.
Not available
S-EPMC11744981 | biostudies-literature
ProteomicsDiscovery of novel CRBN ligands by virtual screening and biological evaluation against multiple hematological cancer cell lines
Immunomodulatory drugs, functioning as cereblon (CRBN) E3 ligase ligands, have been approved for treating various hematological malignancies by hijacking the function of CRBN E3 ligase and inducing the degradation of multiple CRBN-associated substrates. However, the inevitable emergence of drug resi...
ORGANISM(S): Homo sapiens (Human) 
2025-10-13 | PXD061290 | Pride
Hematological cancer  imids  crbn ligands  molecular docking  antitumor evaluation 
UnknownGenome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide.
Not available
S-EPMC7055313 | biostudies-literature
TranscriptomicsCC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL
Cereblon (CRBN), a substrate receptor of the E3 ubiquitin ligase complex CRL4CRBN, is the target of the immunomodulatory drugs lenalidomide and pomalidomide. Recently, it was demonstrated that binding of these drugs to CRBN promotes the ubiquitination and subsequent degradation of two common substra...
ORGANISM(S): Homo sapiens 
2015-11-26 | E-GEOD-75420 | biostudies-arrayexpress
Sort   by:  
 Page size